Candel Therapeutics (Candel Therapeutics) Profitability Rank : 0 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Candel Therapeutics Profitability Rank?

Candel Therapeutics has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Candel Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 was %. As of today, Candel Therapeutics's Piotroski F-Score is 2.

Competitive Comparison of Candel Therapeutics's Profitability Rank

For the Biotechnology subindustry, Candel Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Candel Therapeutics's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Candel Therapeutics's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Candel Therapeutics's Profitability Rank falls into.

Candel Therapeutics Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Candel Therapeutics has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Candel Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %	=	Operating Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-7.902	/	0
	=	%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Candel Therapeutics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank

Candel Therapeutics Profitability Rank Related Terms

Thank you for viewing the detailed overview of Candel Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Candel Therapeutics (Candel Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Candel Therapeutics Inc (NAS:CADL) » Definitions » Profitability Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

117 Kendrick Street, Suite 450, Needham, MA, USA, 02494

Website

https://www.candeltx.com

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Executives

Nicoletta Loggia	director	CANDEL THERAPEUTICS, INC., 117 KENDRICK ST., SUITE 450, NEEDHAM MA 02494
Jason Amello	officer: Chief Financial Officer	500 KENDALL STREET, CAMBRIDGE MA 01824
Paul Peter Tak	director, officer: President & CEO	CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Christopher Martell	director	CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Seshu Tyagarajan	officer: See Remarks	CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Joseph C Papa	director	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Francesca Barone	officer: Chief Scientific Officer	CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
William Garrett Nichols	officer: Chief Medical Officer	C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Gary J. Nabel	director	C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Renee Gaeta	director	C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Paul B Manning	director	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Diem Nguyen	director	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Nathan Caffo	officer: Chief Business Officer	C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
John J Canepa	officer: Chief Financial Officer	241 MATTINSON DRIVE, CONCORD MA 01742
Susan B. Stewart	officer: Chief Regulatory Officer	C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142